Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Clin Cancer Res. 2018 Apr 10;24(14):3433–3446. doi: 10.1158/1078-0432.CCR-17-2793

Figure 3. Differentially expressed GR target genes following GR antagonism.

Figure 3.

Genome-wide gene expression profiling was performed on MDA-MB-231 cells treated with GC (Dex) or GC/antagonist. (A) Total number of up- and downregulated genes by Dex or Dex/GR inhibitor treatment (relative to vehicle); (B) Subset of Dex-regulated genes (≥1.3-fold Dex vs. vehicle) reversed by C297 and/or Mif at 4, 8, and 12h by ≥25 percent change. (C) GR antagonist-identified genes ((B), n=3,066) overlapped with genes (n=5,170) that were differentially expressed between GR-high versus GR-low primary tumors (30). N=462 genes were overlapped.